SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
China Dasheng Biotechnology Company (CDBT) .
本页证实的标准:
- VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。
SharesGrow 综合评分： 28/100 其中 0/7 项标准通过。
SharesGrow 7-Criteria Score
✗
健康
0/100
Debt-to-Equity & liquidity
→ Health
估值概览 — CDBT
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.00
EV/EBITDA0.0
每股数据
EPS (TTM)$-0.02
每股账面价值$0.00
每股营收$0.00
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2004 |
$0.00 |
$630.69K |
$-22.75K |
-3.6% |
| 2005 |
$0.00 |
$484.84K |
$-16.86K |
-3.5% |
| 2006 |
$-0.01 |
$0.00 |
$-68.45K |
- |
| 2007 |
$0.15 |
$16.29M |
$4.64M |
28.5% |
| 2021 |
$0.00 |
$0.00 |
$0.00 |
- |
| 2022 |
$-0.02 |
$0.00 |
$-967K |
- |
